Code financing puts it in top 10 for 2022 series A rounds

As more established gene therapy technologies have faced safety issues, investors are seeking alternatives that can deliver on the promise of the modality. Code is capitalizing on that interest, raising an upsized series A financing that puts the deal in the top 10 for A rounds in 2022.

On Tuesday, the Pennsylvania biotech announced that it had raised $75 million in the round, which was led by new investor Northpond Ventures. The deal will enable Code Biotherapeutics Inc. to advance its two lead programs targeting Duchenne muscular dystrophy (DMD) and Type I diabetes into IND-enabling studies...